Title:
GIPR ANTIBODY, FUSION PROTEIN THEREOF WITH FGF21, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/051802
Kind Code:
A1
Abstract:
Provided are a GIPR antibody, a fusion protein thereof with FGF21, a pharmaceutical composition thereof, and use thereof. Further provided is a method of the GIPR antibody and the fusion protein thereof with FGF21 for treating, preventing or improving one or a plurality of symptoms of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, obesity, or Type 2 diabetes.
Inventors:
WANG XIAOFENG (CN)
ZHANG HUA (CN)
ZHANG CHENG (CN)
JING SHUQIAN (CN)
ZHANG HUA (CN)
ZHANG CHENG (CN)
JING SHUQIAN (CN)
Application Number:
PCT/CN2023/117637
Publication Date:
March 14, 2024
Filing Date:
September 08, 2023
Export Citation:
Assignee:
GMAX BIOPHARM LLC (CN)
International Classes:
C07K16/28; A61K39/395; A61P3/04; A61P3/10; C07K14/50; C07K19/00; C12N15/13; C12N15/62
Domestic Patent References:
| WO2019179424A1 | 2019-09-26 | |||
| WO2018136440A1 | 2018-07-26 | |||
| WO2018237097A1 | 2018-12-27 | |||
| WO2021052349A1 | 2021-03-25 | |||
| WO2021202013A1 | 2021-10-07 |
Foreign References:
| CN112521501A | 2021-03-19 | |||
| CN101993496A | 2011-03-30 |
Other References:
CHEN, JIAWEI ET AL.: "Chronic treatment with anti-GIPR mAb alone and combined with DPP-4 inhibitor correct obesity, dyslipidemia and nephropathy in rodent animals", LIFE SCIENCES, vol. 269, 13 January 2021 (2021-01-13), XP086492981, DOI: 10.1016/j.lfs.2021.119038
HILL CRISTAL M., ALBARADO DIANA C., COCO LUCIA G., SPANN REDIN A., KHAN MD SHAHJALAL, QUALLS-CREEKMORE EMILY, BURK DAVID H., BURKE: "FGF21 is required for protein restriction to extend lifespan and improve metabolic health in male mice", NATURE COMMUNICATIONS, NATURE PUBLISHING GROUP, UK, vol. 13, no. 1, 7 April 2022 (2022-04-07), UK, pages 1897, XP093146899, ISSN: 2041-1723, DOI: 10.1038/s41467-022-29499-8
LU SHU-CHEN, CHEN MICHELLE, ATANGAN LARISSA, KILLION ELIZABETH A., KOMOROWSKI RENEE, CHENG YUAN, NETIROJJANAKUL CHAWITA, FALSEY JA: "GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys (including Supplementary Information)", CELL REPORTS MEDICINE, vol. 2, no. 5, 1 May 2021 (2021-05-01), pages 100263, XP093020708, ISSN: 2666-3791, DOI: 10.1016/j.xcrm.2021.100263
KILLION ELIZABETH A., WANG JINGHONG, YIE JUNMING, SHI STONE D.-H., BATES DARREN, MIN XIAOSHAN, KOMOROWSKI RENEE, HAGER TODD, DENG : "Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models", SCIENCE TRANSLATIONAL MEDICINE, vol. 10, no. 472, 19 December 2018 (2018-12-19), pages eaat3392, XP093146902, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aat3392
HILL CRISTAL M., ALBARADO DIANA C., COCO LUCIA G., SPANN REDIN A., KHAN MD SHAHJALAL, QUALLS-CREEKMORE EMILY, BURK DAVID H., BURKE: "FGF21 is required for protein restriction to extend lifespan and improve metabolic health in male mice", NATURE COMMUNICATIONS, NATURE PUBLISHING GROUP, UK, vol. 13, no. 1, 7 April 2022 (2022-04-07), UK, pages 1897, XP093146899, ISSN: 2041-1723, DOI: 10.1038/s41467-022-29499-8
LU SHU-CHEN, CHEN MICHELLE, ATANGAN LARISSA, KILLION ELIZABETH A., KOMOROWSKI RENEE, CHENG YUAN, NETIROJJANAKUL CHAWITA, FALSEY JA: "GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys (including Supplementary Information)", CELL REPORTS MEDICINE, vol. 2, no. 5, 1 May 2021 (2021-05-01), pages 100263, XP093020708, ISSN: 2666-3791, DOI: 10.1016/j.xcrm.2021.100263
KILLION ELIZABETH A., WANG JINGHONG, YIE JUNMING, SHI STONE D.-H., BATES DARREN, MIN XIAOSHAN, KOMOROWSKI RENEE, HAGER TODD, DENG : "Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models", SCIENCE TRANSLATIONAL MEDICINE, vol. 10, no. 472, 19 December 2018 (2018-12-19), pages eaat3392, XP093146902, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aat3392
Attorney, Agent or Firm:
JUN HE LAW OFFICES (CN)
Download PDF: